Drug | Drug target | Cancer type (or types) | Somatic markers |
---|---|---|---|
Cetuximab | EGFR | Colorectal, head and neck | EGFR and KRAS |
Erlotinib | EGFR | Lung, pancreatic | EGFR |
Exemestane | Aromatase | Breast | ESR1, ESR2 and PGR |
Gefitinib | EGFR | Lung | EGFR |
Imatinib | BCR–ABL, KIT and PDGFRa tyrosine kinases | Chronic myeloid leukaemia, gastrointestinal | Philadelphia chromosome, KIT and PDGFRA |
Lapatinib | ERBB2 receptor | Breast | ERBB2 |
Letrozole | Aromatase | Breast | ESR1, ESR2 and PGR |
Panitumumab | EGFR | Colorectal | EGFR and KRAS |
Tamoxifen | Oestrogen receptor | Breast | ESR1, ESR2 and PGR |
Trastuzumab | ERBB2 receptor | Breast, stomach | ERBB2 |